18 March 2021>: Clinical Research
Atosiban Combined with Ritodrine for Late Threatened Abortion or Threatened Premature Labor Patients with No Response to Ritodrine: A Clinical Trial
Shuai Fu 1ABC* , Haitian Xie 1DEF* , Yilei Zhong 12BCD* , Qi Xu 1D , Liqiong Zhu 1B , Hanjie Mo 1B , Jianping Zhang 1AG , Yinglin Liu 1CF , Hui Chen 1AG , Yonghong Zhong 2AD* , Jianping Tan 1AD*DOI: 10.12659/MSM.929743
Med Sci Monit 2021; 27:e929743
Table 4 Dosage and pregnancy outcomes. Categorical data are shown as a frequency (percentage) and continuous data are shown as mean±SD. The t test was used for analyzing quantitative data, while the χ2 test was used for analyzing categorical data. P<0.05 was considered statistically significant.
Items | Control group (n=22) | Research group (n=30) | P |
---|---|---|---|
Extension of gestation (days) | 93.55±42.29 | 42.53±31.70 | * |
Mean infusion rate of ritodrine (drops/min) | 6.68±2.46 | 6.67±1.92 | 0.980 |
Fetal loss rate (%) | 13.64 (3/22) | 26.67 (8/30) | 0.257 |
Newborn birth weight (kg) | 2.47±0.98 | 1.95±0.94 | 0.063 |
Apgar score at 1 minute | 8.70±1.53 | 8.36±2.08 | 0.560 |
* |